Wedbush cuts Sana Biotechnology stock price target on model changes

Wedbush reduced its price target for Sana Biotechnology (NASDAQ:SANA) to $10 from $22, maintaining an Outperform rating. The change reflects model adjustments, excluding hidradenitis suppurativa and updating financing assumptions. Sana's shares have fallen 42% over the past year, trading at $2.40. The company reported a narrower-than-expected Q2 loss of $0.13 per share and holds $160.5 million in cash.

Original reporting
Published Nov 9, 2026, 3:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$SANA
Bearish
high confidence
Mentioned
$SANA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SANABearishMed
01

Why it matters

Analyst target cuts often trigger short‑term price declines, especially for cash‑intensive biotech firms.

02

Market read

The downgrade is a fresh analyst action that can influence trader decisions on SANA today.

03

What to watch

The recent Q2 earnings beat and improved cash position could mitigate concerns about cash burn.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Wedbush's valuation model adjustments removed hidradenitis suppurativa and changed financing assumptions, leading to a lower target.

Company-level read

Ticker impact

$SANABearishHigh confidence
Context

Wedbush lowered its price target for Sana Biotechnology to $10 from $22, citing model changes and cash burn concerns.

Expected impact

likely pressure as the market prices in the reduced target and cash‑burn concerns

Evidence & confidence

Analyst price‑target revisions are a direct catalyst; the new target implies over 300% upside from current price but reflects a more conservative outlook, prompting short‑term sell pressure.

Market effects

May weigh on other small‑cap biotech stocks as analysts reassess cash‑burn models.

Limited to U.S. biotech sector, no broader regional effect.

Minimal global impact; primarily a company‑specific signal.

Counterpoint

Despite the target cut, the stock still trades far below the new $10 target, offering a potential upside play for risk‑tolerant investors.

Key entities

  • Wedbush Securities

    Provided the revised price target and maintained Outperform rating.

  • Sana Biotechnology

    Biotech firm whose target was revised.

Related articles

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.

$SANAHigh

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on pu

$AVAIMedAI 8/10

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

AVAI Bio, Vertex, and Sana are developing treatments for Type 1 diabetes by replacing insulin-producing beta cells. Vertex's trial showed 10/12 patients stopped using insulin, but all require immunosuppression. Sana's gene-edited cells evaded immune detection. AVAI Bio's joint venture, Insulinova, is testing encapsulated beta cells with Ospedale San Raffaele. No trials or timelines have been announced.

$SANAMed

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology, Inc. (SANA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continu

$YELPMedAI 8/10

Yelp Inc. notified employees of a workforce reduction that is expected to impact nearly 5% of our full-time employees

YELP INC (YELP) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On November 18, 2026, Yelp Inc. (the “Company,” “Yelp,” “we” and “our”) notified employees of a workforce reduction that is expected to impact nearly 5% of our full-time employees. Consistent with our disciplined approach to expense management, we are tak